These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1082 related items for PubMed ID: 28128575

  • 1. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R, Štulc T, Votavová L, Schwarzová L, Vaclová M, Freiberger T.
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [Abstract] [Full Text] [Related]

  • 2. [Severe familial hypercholesterolemia treatment].
    Vrablík M, Freiberger T, Bláha V, Češka R.
    Vnitr Lek; 2016; 62(11):895-901. PubMed ID: 28128576
    [Abstract] [Full Text] [Related]

  • 3. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
    Aljenedil S, Ruel I, Watters K, Genest J.
    J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
    [Abstract] [Full Text] [Related]

  • 4. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V, Bláha M, Lánská M, Havel E, Vyroubal P, Zadák Z, Žák P.
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [Abstract] [Full Text] [Related]

  • 5. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G, Tziomalos K.
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [Abstract] [Full Text] [Related]

  • 6. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ, Hovingh GK, Catapano AL.
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [Abstract] [Full Text] [Related]

  • 7. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 11. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT, Al-Abri A, Al-Dhuhli H, Al-Waili K, Al-Sabti H, Al-Yaarubi S, Al-Hashmi K, Banerjee Y, Al-Zakwani I, Al-Rasadi K.
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA, Hooper AJ, Watts GF, Burnett JR.
    Vasc Health Risk Manag; 2012 May; 8():651-9. PubMed ID: 23226021
    [Abstract] [Full Text] [Related]

  • 14. Modern Management of Familial Hypercholesterolemia.
    Duell PB, Jialal I.
    Metab Syndr Relat Disord; 2016 Dec; 14(10):463-467. PubMed ID: 27797643
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
    Yamashita S, Masuda D, Harada-Shiba M, Arai H, Bujo H, Ishibashi S, Daida H, Koga N, Oikawa S.
    J Atheroscler Thromb; 2022 May 01; 29(5):608-638. PubMed ID: 33980760
    [Abstract] [Full Text] [Related]

  • 16. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
    Taylan C, Schlune A, Meissner T, Ažukaitis K, Udink Ten Cate FE, Weber LT.
    J Clin Lipidol; 2016 May 01; 10(6):1303-1310. PubMed ID: 27919346
    [Abstract] [Full Text] [Related]

  • 17. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L, Plana N, Pérez-Calahorra S, Ibarretxe D, Lamiquiz-Moneo I, Pedro-Botet J, Suárez-Tembra M, Valdivielso P, Ortega E, Civeira F, Dyslipidemia Registry of the Spanish Arteriosclerosis Society.
    Atherosclerosis; 2017 Jul 01; 262():107-112. PubMed ID: 28531826
    [Abstract] [Full Text] [Related]

  • 18. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M, Raslová K, Vohnout B, Blaha V, Satny M, Kyselak O, Vaclova M, Urbanek R, Maskova J, Soska V, Freiberger T.
    Atherosclerosis; 2018 Oct 01; 277():355-361. PubMed ID: 30270071
    [Abstract] [Full Text] [Related]

  • 19. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
    Schaefer JR, Kurt B, Sattler A, Klaus G, Soufi M.
    Clin Res Cardiol Suppl; 2012 Jun 01; 7(Suppl 1):2-6. PubMed ID: 22528129
    [Abstract] [Full Text] [Related]

  • 20. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG, Dufour R, Davignon J, Baass A.
    Arterioscler Thromb Vasc Biol; 2014 Dec 01; 34(12):2700-5. PubMed ID: 25278291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.